Tesi etd-10202025-120447 |
Link copiato negli appunti
Tipo di tesi
Tesi di specializzazione (4 anni)
Autore
ADAMO, GIULIA
URN
etd-10202025-120447
Titolo
Serum Eotaxin-3 and IL-10 are useful non-invasive biomarkers for the diagnosis and identification of histological remission of eosinophilic esophagitis: a prospective study
Dipartimento
RICERCA TRASLAZIONALE E DELLE NUOVE TECNOLOGIE IN MEDICINA E CHIRURGIA
Corso di studi
MALATTIE DELL'APPARATO DIGERENTE
Relatori
relatore Prof. de Bortoli, Nicola
correlatore Prof. Puxeddu, Ilaria
correlatore Prof. Puxeddu, Ilaria
Parole chiave
- biomarkers
- eosinophilic esophagitis
- eotassine
- eotaxin
- esofagite eosinofila
- non-invasive biomarkers
Data inizio appello
10/11/2025
Consultabilità
Non consultabile
Data di rilascio
10/11/2065
Riassunto
Background: Eosinophilic esophagitis (EoE) diagnosis and monitoring still rely on invasive esophagogastroduodenoscopy (EGD) with biopsies. Non-invasive biomarkers are therefore needed. This study prospectively assessed the diagnostic and follow-up value of serum Eotaxin-1, Eotaxin-2, Eotaxin-3, IL-4, IL-5, and IL-10 in adult EoE patients.
Methods: Adults (≥18 years) with new EoE (≥15 eosinophils/HPF) were enrolled. At baseline (T0), all underwent EGD with six biopsies. After standard therapy, histological remission was reassessed at 12 weeks (T1). Serum cytokine levels were measured at T0 and T1 and compared with age-, sex-, and atopy-matched healthy controls (HCs).
Results: Twenty-five EoE patients and fourteen HCs were included. At T0, EoE patients had higher Eotaxin-3 (501 vs. 224 pg/mL, p=0.002) and IL-10 (100 vs. 56 pg/mL, p=0.01). Eotaxin-3 ≥389 pg/mL (AUC=0.80; 93% specificity; 68% sensitivity) and IL-10 ≥168 pg/mL (AUC=0.74; 100% specificity; 44% sensitivity) identified active EoE. After treatment, 18/25 (72%) achieved remission, showing lower Eotaxin-3 (252 vs. 501 pg/mL, p=0.02) and IL-10 (67 vs. 100 pg/mL, p<0.05). Remission cut-offs were 241 pg/mL for Eotaxin-3 (AUC=0.70) and 199.5 pg/mL for IL-10 (AUC=0.68). Conclusions: Serum Eotaxin-3 and IL-10 are promising non-invasive biomarkers for diagnosing and monitoring eosinophilic esophagitis.
Methods: Adults (≥18 years) with new EoE (≥15 eosinophils/HPF) were enrolled. At baseline (T0), all underwent EGD with six biopsies. After standard therapy, histological remission was reassessed at 12 weeks (T1). Serum cytokine levels were measured at T0 and T1 and compared with age-, sex-, and atopy-matched healthy controls (HCs).
Results: Twenty-five EoE patients and fourteen HCs were included. At T0, EoE patients had higher Eotaxin-3 (501 vs. 224 pg/mL, p=0.002) and IL-10 (100 vs. 56 pg/mL, p=0.01). Eotaxin-3 ≥389 pg/mL (AUC=0.80; 93% specificity; 68% sensitivity) and IL-10 ≥168 pg/mL (AUC=0.74; 100% specificity; 44% sensitivity) identified active EoE. After treatment, 18/25 (72%) achieved remission, showing lower Eotaxin-3 (252 vs. 501 pg/mL, p=0.02) and IL-10 (67 vs. 100 pg/mL, p<0.05). Remission cut-offs were 241 pg/mL for Eotaxin-3 (AUC=0.70) and 199.5 pg/mL for IL-10 (AUC=0.68). Conclusions: Serum Eotaxin-3 and IL-10 are promising non-invasive biomarkers for diagnosing and monitoring eosinophilic esophagitis.
File
| Nome file | Dimensione |
|---|---|
La tesi non è consultabile. |
|